About Time: Assessing Time Spent in Urology Ambulatory Visits and Patient Race

Abstract

Racial disparities in the diagnosis, treatment, and outcomes of many urologic diseases are well-documented. Nationally, Black men are more than twice as likely to die of prostate cancer as white men, with both higher incidence and worse outcomes after diagnosis.1 Bladder cancer survival is also lower, as Black patients present with more advanced disease and have lower rates of receipt of optimal treatment.2,3 Clearly, a complex interplay between biology, access, patterns of care, and socioeconomic and cultural factors affects how vulnerable populations with urologic pathologies fare.